Avadel Pharmaceuticals plc

NasdaqGM AVDL

Avadel Pharmaceuticals plc Price to Sales Ratio (P/S) on December 30, 2024: 7.32

Avadel Pharmaceuticals plc Price to Sales Ratio (P/S) is 7.32 on December 30, 2024, a -85.00% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Avadel Pharmaceuticals plc 52-week high Price to Sales Ratio (P/S) is 56.50 on March 22, 2024, which is 671.53% above the current Price to Sales Ratio (P/S).
Avadel Pharmaceuticals plc 52-week low Price to Sales Ratio (P/S) is 6.93 on December 03, 2024, which is -5.33% below the current Price to Sales Ratio (P/S).
Avadel Pharmaceuticals plc average Price to Sales Ratio (P/S) for the last 52 weeks is 24.17.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqGM: AVDL

Avadel Pharmaceuticals plc

CEO	Mr. Gregory J. Divis Jr.
IPO Date	June 7, 1996
Location	Ireland
Headquarters	10 Earlsfort Terrace
Employees	154
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Key trends

Past 5 years